MESO
Price
$15.60
Change
-$0.89 (-5.40%)
Updated
Aug 14 closing price
Capitalization
2.02B
18 days until earnings call
Intraday BUY SELL Signals
SRPT
Price
$18.10
Change
-$0.32 (-1.74%)
Updated
Aug 14 closing price
Capitalization
1.91B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MESO vs SRPT

MESO vs SRPT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MESO vs. SRPT commentary
Aug 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MESO is a Hold and SRPT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2026
Stock price -- (MESO: $15.60 vs. SRPT: $18.10)
Brand notoriety: MESO: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MESO: 57% vs. SRPT: 35%
Market capitalization -- MESO: $2.02B vs. SRPT: $1.91B
MESO [@Biotechnology] is valued at $2.02B. SRPT’s [@Biotechnology] market capitalization is $1.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $128.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MESO’s FA Score shows that 0 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • MESO’s FA Score: 0 green, 5 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, both MESO and SRPT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MESO’s TA Score shows that 6 TA indicator(s) are bullish while SRPT’s TA Score has 6 bullish TA indicator(s).

  • MESO’s TA Score: 6 bullish, 4 bearish.
  • SRPT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both MESO and SRPT are a good buy in the short-term.

Price Growth

MESO (@Biotechnology) experienced а -2.16% price change this week, while SRPT (@Biotechnology) price change was +7.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.51%. For the same industry, the average monthly price growth was -1.43%, and the average quarterly price growth was +2992.28%.

Reported Earning Dates

MESO is expected to report earnings on Sep 02, 2026.

SRPT is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (+0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MESO($2.03B) has a higher market cap than SRPT($1.91B). MESO YTD gains are higher at: -13.553 vs. SRPT (-15.892). SRPT has higher annual earnings (EBITDA): 125M vs. MESO (-71.46M). SRPT has more cash in the bank: 653M vs. MESO (130M). MESO has less debt than SRPT: MESO (135M) vs SRPT (1.04B). SRPT has higher revenues than MESO: SRPT (2.18B) vs MESO (65.4M).
MESOSRPTMESO / SRPT
Capitalization2.03B1.91B106%
EBITDA-71.46M125M-57%
Gain YTD-13.553-15.89285%
P/E RatioN/A45.49-
Revenue65.4M2.18B3%
Total Cash130M653M20%
Total Debt135M1.04B13%
FUNDAMENTALS RATINGS
MESO vs SRPT: Fundamental Ratings
MESO
SRPT
OUTLOOK RATING
1..100
313
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
9785
PRICE GROWTH RATING
1..100
5253
P/E GROWTH RATING
1..100
9777
SEASONALITY SCORE
1..100
25n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRPT's Valuation (85) in the Biotechnology industry is in the same range as MESO (94). This means that SRPT’s stock grew similarly to MESO’s over the last 12 months.

MESO's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as SRPT (100). This means that MESO’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (85) in the Biotechnology industry is in the same range as MESO (97). This means that SRPT’s stock grew similarly to MESO’s over the last 12 months.

MESO's Price Growth Rating (52) in the Biotechnology industry is in the same range as SRPT (53). This means that MESO’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's P/E Growth Rating (77) in the Biotechnology industry is in the same range as MESO (97). This means that SRPT’s stock grew similarly to MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MESOSRPT
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 25 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
MESO
Daily Signal:
Gain/Loss:
SRPT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PDP142.581.18
+0.84%
Invesco Dorsey Wright Momentum ETF
GREK82.850.60
+0.72%
Global X MSCI Greece ETF
OASC35.650.21
+0.59%
OneAscent Enhanced Small and Mid Cap ETF
QEW30.86-0.03
-0.11%
Invesco QQQ Equal Weight ETF
TXXI50.15-0.11
-0.22%
Bondbloxx IR+M Tax-Aware Intermediate Duration ETF

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with RCKT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-1.74%
RCKT - SRPT
43%
Loosely correlated
+3.89%
AXON - SRPT
43%
Loosely correlated
-0.45%
DNLI - SRPT
43%
Loosely correlated
-1.69%
SANA - SRPT
43%
Loosely correlated
-3.27%
CRBU - SRPT
42%
Loosely correlated
-1.86%
More